ClinicalTrials.gg
CompletedNCT06353451Updated Apr 9, 2024

Digital Detox Study: A Randomized Controlled Trial

An interventional study of Digital Detox in Health Behavior, sponsored by Danube University Krems. Completed at 1 site in Austria. Open to participants aged 18 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-09.

Sponsored by Danube University Krems · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2023, registered Mar 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 29 Years
Sex
All
01

Study summary

The aim of the present RCT is to investigate the effect of smartphone screen time reduction on mental health indicators in healthy, 18-29 yo Austrian students.

After inclusion and randomization to intervention- and control group, normal screen time behavior will be assessed for 10-days. After that, the mental health parameters will be carried out in both groups as a baseline survey (T0). After that, intervention group should limit smartphone screen time to less than 2 hours per day for three consecutive weeks. Control group should use smartphones as usual. After that, mental health parameters will be assessed again in both groups (post-intervention, T1). After T1, there are no further requirements regarding screen time. Mental health parameters will be assessed again in both groups at follow-up (T2).

Main outcome parameters are 1) Well-Being (WHO-5), depressive symptoms (PHQ-9), stress (PSQ-20), and sleep quality (ISI).

The primary hypothesis (stated at Open Science Framework before Enrollment: https://osf.io/a9k76) is that mental health indicators, particularly stress, depressive symptoms, and sleep quality will improve throughout the intervention compared to the control group as well as to baseline.

Read the detailed description

According to the power-analysis (small to medium effect size of d=.45, power .8, significance level \< .05, icc = .05), a sample of N > 100 should be recruited through newsletter, notices and social media. The inclusion criteria are more than 3 hours of screen time per day, no mental disorder, no ongoing psychotherapy or use of psychotropic drugs.

After signing the informed consent, participants have to download an App (ESMira®), which processes the whole study. The first step is to fill out sociodemographic data, smartphone use and mental health questionnaires. After controlling for inclusion- and exclusion criteria, ESMira will randomize into intervention- (IG) and control group (CG). Participants in the control group (CG) should continue their smartphone behavior unchanged throughout the entire study period. Participants in the intervention group (IG) should continue their smartphone usage unchanged for the first 10 days (Baseline.) After that, the mental health parameters will be carried out in both groups as a baseline survey (T0). After that, participants of the intervention group should limit their smartphone screen time under two hours per day for three weeks. To comply with that, participants should use the limiter function of their smartphone or download an additional app. A screen shot of the screen time has to be uploaded weekly on Monday for the previous week (Monday to Sunday). At the end of the intervention (t1), the mental health questionnaires will be collected again in both groups. After T1, there are no further requirements regarding screen time. Mental health parameters will be assessed again in both groups at follow-up (T2).

During the study period participants will be asked to additionally wear a fitness tracker to measure daily movement as well as objective stress parameters.

Data collection and randomization The whole data collection procedure will be carried out through the ESMira App. ESMira is a tool for running longitudinal studies (ESM, AA, EMA, ...) with completely anonymized communication with participants and data collection.

Smartphone screen time Weekly screen time will be documented in both groups using the smartphones' built-in screen time measurements.

Statistical plan

Repeated measurements ANOVAs (rm-ANOVA) will be applied to analyze differences. Difference between t0 (baseline) and t1 (post-intervention) in the intervention group and on the difference between control group and intervention group are the primary hypotheses. Effects (between- as well as within group) will be analyzed for all 3 measurement points as well. Furthermore, a secondary analysis will be applied to analyze the sub-sample that strictly adhered to the time limits.

In case of baseline group-differences, variables will be added as covariates in the rm-ANOVA. A Greenhouse-Geisser correction will be applied, if sphericity assumption is violated. In the post hoc tests, Bonferroni correction will be applied to adjust for multiple comparisons.

Missing values will be dealt with via maximum likelihood estimation. Percentage changes in the main outcomes between baseline and post-intervention will be calculated.

02

Conditions studied

  • Health Behavior

Browse trials for

Keywords

  • Smartphone screen time
  • Digital Detox
  • Social Media Detox
03

In context

Health Behavior

970 studies on the registry are indexed under Health Behavior; 166 are open to participants now.

This study's enrollment of 111 is below the median of 150 across 826 interventional studies indexed under Health Behavior.

Browse Health Behavior studies →

Lead sponsor

Danube University Krems is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 29 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-29 years old
  • male/female
  • daily screen time > 3 h/d
  • no mental disorder
  • no ongoing psychotherapy
  • no psychotropic drugs

Exclusion criteria

Exclusion Criteria:

  • \< 18 yo or > 29 yo
  • daily screen time \< 3 h/d
  • mental disorder (self-statement)
  • in ongoing psychotherapy
  • psychotropic drug use
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Intervention Group

    Smartphone screen time should be reduced to less than 2 hours per day for 3 consecutive weeks. Screen time will be controlled by screenshots weekly.

    Behavioral: Digital Detox

  • No intervention
    Control group

    Smartphone usage behavior should continue unchanged. Screen time will be measured by uploaded screenshots weekly.

Interventions

  • BehavioralDigital Detox

    In the intervention group, smartphone screen time will be reduced to less than 2 hours for 3 consecutive weeks.

06

What researchers measure

Primary outcomes

  1. Depressive Symptoms

    Patient Health Questionnaire (PHQ-9): The PHQ-9 contains nine self-rating items on a four-point scale ranging from 0 ("not at all") to 3 ("nearly every day"), resulting in a total score from 0 to 27. Higher scores indicate more depressive symptoms.

    Time frame: The questionnaire will be assessed at 3 time points, 1) at baseline (=immediately pre-intervention (t0), 2) immediatly after the 3-week intervention (t1), and 3) at Follow-Up (t2= six weeks post intervention).

  2. Stress

    Perceived Stress Questionnaire (PSQ-20): Each item is rated from almost never (=1) to usually (= 4), with a sum score from 20 to 80. Higher scores indicate more stress.

    Time frame: The questionnaire will be assessed at 3 time points, 1) at baseline (=immediately pre-intervention (t0), 2) immediatly after the 3-week intervention (t1), and 3) at Follow-Up (t2= six weeks post intervention).

  3. Sleep Quality

    Insomnia Severity Index (ISI): The ISI comprises 7 self-reported items, each rated on a scale from 0 to 4, resulting in sum scores from 0 to 28. Higher scores indicate more insomnia symptoms or less sleep quality.

    Time frame: The questionnaire will be assessed at 3 time points, 1) at baseline (=immediately pre-intervention (t0), 2) immediatly after the 3-week intervention (t1), and 3) at Follow-Up (t2= six weeks post intervention).

  4. Well-being

    World Health Organization well-being questionnaire (WHO-5): The WHO-5 contains 5 items (0 to 5 points). Scores range from 0 (no well-being) to 25 points (maximal well-being).

    Time frame: The questionnaire will be assessed at 3 time points, 1) at baseline (=immediately pre-intervention (t0), 2) immediatly after the 3-week intervention (t1), and 3) at Follow-Up (t2= six weeks post intervention).

Secondary outcomes

  1. Problematic smartphone use

    Smartphone Addiction Scale Short Version (SAS-SV): The 10 items range from 1 (=strongly disagree) to 6 (=strongly agree) points with a sum score from 10 to 60. Higher scores indicate problematic smartphone use.

    Time frame: The questionnaire will be assessed at 3 time points, 1) at baseline (=immediately pre-intervention (t0), 2) immediatly after the 3-week intervention (t1), and 3) at Follow-Up (t2= six weeks post intervention).

  2. Body Appreciation

    Body Appreciation Scale-2 (BAS-2): The scale is comprised of 10 items, which can be rated from "never" (1) to "always" (5). Higher scores indicate a more positive body appreciation.

    Time frame: The questionnaire will be assessed at 3 time points, 1) at baseline (=immediately pre-intervention (t0), 2) immediatly after the 3-week intervention (t1), and 3) at Follow-Up (t2= six weeks post intervention).

  3. Anxiety Symptoms

    Generalized Anxiety Disorder 7 scale (GAD-7): The GAD-7 contains 7 self-rating items on a four-point scale, from 0 to 3 (maximum score 21). Higher scores indicate more anxiety symptoms.

    Time frame: The questionnaire will be assessed at 3 time points, 1) at baseline (=immediately pre-intervention (t0), 2) immediatly after the 3-week intervention (t1), and 3) at Follow-Up (t2= six weeks post intervention).

  4. Eating Disorder

    SCOFF (Sick, Controll, One stone, Fat, Food) Questionnaire: Five items can be answered with "yes"=1 or "no"=0. The total score ranges from 0 to 5. A total score of 2 or above indicates disordered eating.

    Time frame: The questionnaire will be assessed at 3 time points, 1) at baseline (=immediately pre-intervention (t0), 2) immediatly after the 3-week intervention (t1), and 3) at Follow-Up (t2= six weeks post intervention).

Other outcomes

  1. Physical Activity

    Physical activity (moderate to high intensity physical activity in minutes per day) was assessed with a Fitness Tracker (Fitbit® Inspire 3).

    Time frame: Physical activity was recorded from the beginning of the baseline phase for the duration of 5 weeks (2 weeks baseline, 3 weeks intervention) and stopped after intervention (=t1).

  2. Heart rate variability (HRV)

    HRV was measured regularly every day and then an overall score was created for the sleep period using a Fitness Tracker (Fitbit® Inspire 3).

    Time frame: HRV was recorded from the beginning of the baseline phase for the duration of 5 weeks (= 2 weeks baseline, 3 weeks intervention) and stopped after intervention (=t1).

  3. Resting Heart Rate (RHR)

    RHR was measured regularly every day and then an overall score was created for the sleep period using a Fitness Tracker (Fitbit® Inspire 3).

    Time frame: RHR was recorded from the beginning of the baseline phase for the duration of 5 weeks (= 2 weeks baseline, 3 weeks intervention) and stopped after intervention (=t1).

  4. Screen time

    Smartphone screen time will be assessed weekly from November 10th, 20223 until January 21st, 2024 using the smartphones' built-in screen time measurements. Every Monday, participants will received a push-up message via the ESMira app to upload the screenshot from their screen time of the previous week (Monday to Sunday), including the amount spent on social media sites. If necessary, participants received up to three reminders.

    Time frame: Starting with the baseline screening (November 10th, 2023) weekly until Follow-Up (t2=January 21st, 2024)

07

Study locations

1 site
  • Danube University Krems
    Krems, Lower Austria 3500, Austria
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jan 2024, 2 months.

Of 569 non-industry interventional studies with no phase under Health Behavior, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 33. This study's 2 months is below that.

Counting every sponsor, half of 587 studies reached it within 15 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2024
First posted
Apr 9, 2024
StartActual
Oct 23, 2023
Primary completionActual
Jan 21, 2024
CompletionActual
Jan 21, 2024
Last update
Apr 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06353451
Lead sponsor
Danube University Krems
Responsible party
Christoph Pieh (Full Professor and Head of Department, Danube University Krems) — Principal investigator
First posted
Apr 9, 2024
Start date
Oct 23, 2023
Primary completion
Jan 21, 2024
Completion
Jan 21, 2024
Last update
Apr 9, 2024

Study contacts

Christoph Pieh, MD
principal investigator · Danube University Krems

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion